

ASX Announcement

Medibio Limited – 20 February 2023



Update to Share Purchase Plan Timetable

Melbourne, Australia and Minneapolis, MN – 20 February 2023: Medibio Limited (“MEB” or “Medibio”) (ASX: MEB) (OTCPINK: MDBIF) advises that the Share Purchase Plan (SPP) timetable which was announced on 15 February 2023 has been updated as follows.

Event	Date
SPP Record Date	7.00pm (AEDT) Tuesday, 14 February 2023
Announcement to market regarding Placement and SPP	Prior to market open Wednesday, 15 February 2023
ASX Appendix 2A for Placement Shares	Monday, 20 February 2023
Allotment of Placement Shares	Tuesday, 21 February 2023
Lodge SPP Prospectus (providing for SPP Offer and Shortfall Offer)	Before 10.00am (AEDT), Tuesday, 28 February 2023
SPP Offer and SPP Shortfall Offer Opening Date	Tuesday, 28 February 2023
Dispatch of SPP offer documents to eligible shareholders	Tuesday, 28 February 2023
EGM conducted to approve issue of SPP Securities, Tranche 1 Options, Tranche 1 CPS Options and Underwritten SPP Securities (and ratification of Tranche 1 Placement securities)	Thursday, 6 April 2023
SPP Closing Date	Thursday, 6 April 2023
Announcement to market regarding completion of SPP	Wednesday, 12 April 2023
Allotment of SPP Securities	Friday, 14 April 2023

**The above timetable remains as indicative only and subject to change. The quotation of shares is subject to ASX approval. Subject to the ASX Listing Rules and Corporations Act and other applicable laws, the Company reserves the right to vary these dates, without notice. Any extension of the SPP will have a consequential effect on the issue date of the securities.*

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

For Further information:

David Trimboli
Non-Executive Chair
T: +61 3 9692 7222

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

Level 4, 100 Albert Road, South Melbourne, Vic 3205
Email: info@medibio.com.au | www.medibio.com.au
ACN: 008 130 336